37 articles with Medicenna
Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced that it has received US$1,915,264 from the Cancer Prevention and Research Institute of Texas.
Scientists at the NIH and FDA Demonstrate Impressive Synergy of MDNA55 with Interferons
Dr. Merchant will also be available to meet with investors on a one-on-one basis during the conference.
Medicenna Presents Preliminary Top-Line Clinical Results from their Phase 2b Trial of MDNA55 in Recurrent Glioblastoma
Disease control rate of up to 83% achieved; evidence of improved survival for patients
Medicenna To Host Key Opinion Leader Call Focused on MDNA55 Recurrent Glioblastoma Program and Preliminary Top-Line Results
Medicenna Therapeutics Corp. announced that it will host a Key Opinion Leader call and webcast for the investment community on Tuesday, June 18, 2019 at 1 PM, EDT.
Medicenna Therapeutics Corp., a clinical stage Immuno-Oncology company, announced that it will present preliminary top-line results from the recently completed Phase 2b clinical trial of MDNA55 for the treatment of recurrent glioblastoma at the Inaugural Immuno-Oncology Pharma Congress to be held from June 18-20, 2019 during World Pharma Week in Boston, MA.
Medicenna Presents Clinical Validation of the IL4 Receptor as a Biomarker for MDNA55 in Recurrent Glioblastoma
75% of IL4R+ve Patients Achieve Disease Control Following One Treatment With MDNA55
Medicenna Therapeutics Corp. is pleased to announce that Dr. Fahar Merchant, Chairman, President and CEO and Elizabeth Williams, CFO, will present at the upcoming 9th annual LD Micro Invitational on Tuesday, June 4th at 10:20 AM PST / 1:20 PM EST. Dr. Merchant and Ms. Williams will also be meeting with investors at the conference.
Medicenna Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
Medicenna Therapeutics Corp. announced that Dr. Dina Randazzo of Duke University, will present updates related to the recently completed Phase 2b clinical trial of MDNA55 for the treatment of recurrent glioblastoma at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held from May 31 to June 4, 2019 in Chicago, Illinois.
Medicenna Therapeutics Corp. announced that it has received US$757,940 from the Cancer Prevention and Research Institute of Texas.
Medicenna Announces Completion of Enrolment in MDNA55 Phase 2b Recurrent Glioblastoma Clinical Study
Medicenna Therapeutics Corp. is pleased to announce that it has completed enrolment in the Phase 2b clinical study of MDNA55 for the treatment of recurrent glioblastoma, the most common and uniformly fatal form of brain cancer.
Strong interim survival trend (15.2 vs 8.5 months) emerging in IL4R positive patients
Medicenna Shows Promising Pre-Clinical Results in Solid Tumor Models with its IL-2 Superkine, MDNA109
Magnified IL-2 affinity towards CD122 potently synergizes with checkpoint inhibitors
Medicenna Therapeutics Corp. announced today that it has received US$1,224,540 (approximately, CD$1.6M) from the Cancer Prevention and Research Institute of Texas ("CPRIT").
Medicenna Therapeutics Corp. will be presenting an update on previously announced data from the Company's MDNA109 and MDNA55 programs at the following conferences:
Medicenna Therapeutics Corp. today announced promising interim efficacy and safety results from patients treated at low doses in the on-going Phase 2b clinical trial of MDNA55.
Medicenna Presented Insights from the Phase 2b Clinical Trial of MDNA55 at the European Society for Medical Oncology 2018 Congress
Dr. Martin Bexon, Head of Clinical Development at Medicenna, presented results outlining the patterns of responses seen in the MDNA55 Phase 2b clinical trial in patients treated at low doses implemented during the first half of the study.
The MDNA55 Phase 2b clinical trial is for the treatment of recurrent glioblastoma
Announces Notice of Allowance of US Patent for IL-2 Superkine Agonists and Antagonist
Promising Pre-Clinical Efficacy, Safety and Pharmacokinetics Shown by Long-Acting Fusions of MDNA109